FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740573642> ?p ?o ?g. }

• W2740573642 endingPage "58151" @default.
• W2740573642 startingPage "58133" @default.
• W2740573642 abstract "// Marisa D. Santos 1,2 , Cristina Silva 1,2 , Anabela Rocha 1,2 , Carlos Nogueira 1,2 , Fernando Castro-Poças 2,3 , António Araujo 2,4 , Eduarda Matos 5 , Carina Pereira 2,6,7 , Rui Medeiros 2,6,7,8 and Carlos Lopes 2,9,10 1 Department of Surgery, Digestive Surgery Service, Hospital Center of Porto, Porto, Portugal 2 Abel Salazar Biomedical Science Institute, University of Porto, Porto, Portugal 3 Gastroenterology Service, Hospital Center of Porto, Porto, Portugal 4 Service of Medical Oncology, Hospital Center of Porto, Porto, Portugal 5 Department of Health Community, Abel Salazar Biomedical Science Institute, University of Porto, Porto, Portugal 6 Molecular Oncology and Viral Pathology Group, IPO Research Center, Portuguese Oncologic Institute, Porto, Portugal 7 Research Department, Portuguese League Against Cancer, Porto, Portugal 8 CEBIMED, Faculty of Health Sciences of Fernando Pessoa, University of Porto, Porto, Portugal 9 Department of Pathology, Pathological Anatomy Service, Hospital Center of Porto, Porto, Portugal 10 Department of Pathology and Molecular Immunology, Abel Salazar Biomedical Science Institute, University of Porto, Porto, Portugal Correspondence to: Marisa D. Santos, email: // Keywords : neutrophil lymphocyte ratio, molecular marker, neoadjuvant chemoradiation, prediction, rectal cancer Received : March 12, 2017 Accepted : July 18, 2017 Published : July 28, 2017 Abstract Survival improvement in rectal cancer treated with neoadjuvant chemoradiotherapy (nCRT) is achieved only if pathological response occurs. Mandard tumor regression grade (TRG) proved to be a valid system to measure nCRT response. The ability to predict tumor response before treatment may significantly have impact the selection of patients for nCRT in rectal cancer. The aim is to identify potential predictive pretreatment factors for Mandard response and build a clinical predictive model design. 167 patients with locally advanced rectal cancer were treated with nCRT and curative surgery. Blood cell counts in peripheral blood were analyzed. Pretreatment biopsies expression of cyclin D1, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and protein 21 were assessed. A total of 61 single nucleotide polymorphisms were characterized using the Sequenom platform through multiplex amplification followed by mass-spectometric product separation. Surgical specimens were classified according to Mandard TRG. The patients were divided as: “good responders” (Mandard TRG1-2) and “poor responders” (Mandard TGR3-5). We examined predictive factors for Mandard response and performed statistical analysis. In univariate analysis, distance from anal verge, neutrophil lymphocyte ratio (NLR), cyclin D1, VEGF, EGFR, protein 21 and rs1810871 interleukin 10 (IL10) gene polymorphism are the pretreatment variables with predictive value for Mandard response. In multivariable analysis, NLR, cyclin D1, protein 21 and rs1800871 in IL10 gene maintain predictive value, allowing a clinical model design. Conclusion: It seems possible to use pretreatment expression of blood and tissue biomarkers, and build a model of tumor response prediction to neoadjuvant chemoradiation in rectal cancer." @default.
• W2740573642 created "2017-08-08" @default.
• W2740573642 creator A5002735203 @default.
• W2740573642 creator A5016327041 @default.
• W2740573642 creator A5029169105 @default.
• W2740573642 creator A5034941839 @default.
• W2740573642 creator A5035849271 @default.
• W2740573642 creator A5040540920 @default.
• W2740573642 creator A5055846516 @default.
• W2740573642 creator A5070137528 @default.
• W2740573642 creator A5072726329 @default.
• W2740573642 creator A5079894150 @default.
• W2740573642 date "2017-07-28" @default.
• W2740573642 modified "2023-10-17" @default.
• W2740573642 title "Predictive clinical model of tumor response after chemoradiation in rectal cancer" @default.
• W2740573642 cites W1562382168 @default.
• W2740573642 cites W1571831251 @default.
• W2740573642 cites W1587031599 @default.
• W2740573642 cites W1715678724 @default.
• W2740573642 cites W1834357221 @default.
• W2740573642 cites W1912476950 @default.
• W2740573642 cites W1966608551 @default.
• W2740573642 cites W1967193411 @default.
• W2740573642 cites W1968274686 @default.
• W2740573642 cites W1970295158 @default.
• W2740573642 cites W1970340560 @default.
• W2740573642 cites W1972650011 @default.
• W2740573642 cites W1972883640 @default.
• W2740573642 cites W1973101195 @default.
• W2740573642 cites W1977468182 @default.
• W2740573642 cites W1979238043 @default.
• W2740573642 cites W1983388883 @default.
• W2740573642 cites W1984396300 @default.
• W2740573642 cites W1995882620 @default.
• W2740573642 cites W1998179414 @default.
• W2740573642 cites W2010325041 @default.
• W2740573642 cites W2013368318 @default.
• W2740573642 cites W2014958910 @default.
• W2740573642 cites W2017157243 @default.
• W2740573642 cites W2017233105 @default.
• W2740573642 cites W2020659765 @default.
• W2740573642 cites W2023533585 @default.
• W2740573642 cites W2028186534 @default.
• W2740573642 cites W2038580372 @default.
• W2740573642 cites W2040660199 @default.
• W2740573642 cites W2044243545 @default.
• W2740573642 cites W2045382197 @default.
• W2740573642 cites W2045471243 @default.
• W2740573642 cites W2045793425 @default.
• W2740573642 cites W2046075241 @default.
• W2740573642 cites W2046950425 @default.
• W2740573642 cites W2049732557 @default.
• W2740573642 cites W2049783494 @default.
• W2740573642 cites W2050049071 @default.
• W2740573642 cites W2058155176 @default.
• W2740573642 cites W2060706863 @default.
• W2740573642 cites W2068819366 @default.
• W2740573642 cites W2070618028 @default.
• W2740573642 cites W2072341374 @default.
• W2740573642 cites W2072821594 @default.
• W2740573642 cites W2073631512 @default.
• W2740573642 cites W2078928782 @default.
• W2740573642 cites W2079620338 @default.
• W2740573642 cites W2082300679 @default.
• W2740573642 cites W2083813478 @default.
• W2740573642 cites W2085047698 @default.
• W2740573642 cites W2085218834 @default.
• W2740573642 cites W2088619243 @default.
• W2740573642 cites W2089008773 @default.
• W2740573642 cites W2089673328 @default.
• W2740573642 cites W2091495760 @default.
• W2740573642 cites W2099520645 @default.
• W2740573642 cites W2101719692 @default.
• W2740573642 cites W2102229790 @default.
• W2740573642 cites W2103951885 @default.
• W2740573642 cites W2107658298 @default.
• W2740573642 cites W2110251913 @default.
• W2740573642 cites W2117842006 @default.
• W2740573642 cites W2135535670 @default.
• W2740573642 cites W2139264698 @default.
• W2740573642 cites W2143980077 @default.
• W2740573642 cites W2159703742 @default.
• W2740573642 cites W2275233474 @default.
• W2740573642 cites W2314460836 @default.
• W2740573642 cites W2318048315 @default.
• W2740573642 cites W2318417574 @default.
• W2740573642 cites W2416937392 @default.
• W2740573642 cites W4252634980 @default.
• W2740573642 cites W2087383010 @default.
• W2740573642 cites W2215054335 @default.
• W2740573642 doi "https://doi.org/10.18632/oncotarget.19651" @default.
• W2740573642 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5601639" @default.
• W2740573642 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28938543" @default.
• W2740573642 hasPublicationYear "2017" @default.
• W2740573642 type Work @default.
• W2740573642 sameAs 2740573642 @default.
• W2740573642 citedByCount "12" @default.
• W2740573642 countsByYear W27405736422017 @default.

• next